Deprenyl (selegiline) is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor that increases Dopamine availability in the brain by blocking the primary dopamine-degrading enzyme. At low doses (<10mg/day), it maintains MAO-B selectivity; at higher doses, it also inhibits MAO-A and affects Serotonin and norepinephrine metabolism. Used clinically in Parkinson's Disease and as a cognitive enhancer, with particular relevance in cPNI for addressing reward deficiency states and motivational dysfunction.
Think of dopamine-producing neurons as fruit orchards and dopamine molecules as apples. MAO-B is the cleanup crew that comes through daily, removing fallen apples (degrading dopamine) from the ground to keep things tidy. In a healthy orchard, the cleanup crew's work is balanced—enough apples remain for the next day's harvest (synaptic signaling), and enough are removed to prevent rot (excitotoxicity). Deprenyl is like firing half the cleanup crew—specifically, the MAO-B workers who only handle apples, leaving the MAO-A workers (who clean up oranges and pears—serotonin and norepinephrine) still on the job. With fewer cleaners, more apples accumulate on the ground, available for longer periods. The clever twist: deprenyl permanently retires these workers (irreversible inhibition), so even though the drug itself leaves your system in 2 hours, the effect lasts for days until your body trains new cleanup staff (synthesizes new MAO-B enzyme). But there's a complication—some of those retired workers' severance packages convert into weak stimulants (L-methamphetamine and L-amphetamine metabolites), which add a subtle energy boost beyond just apple accumulation.
Deprenyl irreversibly binds to and inhibits monoamine oxidase B (MAO-B), the primary enzyme responsible for metabolizing Dopamine in the striatum and substantia nigra:
Primary Pathway:
MAO-B (mitochondrial enzyme) + Deprenyl → Irreversible covalent bond → Permanent enzyme inactivation → ↑ Dopamine half-life in synaptic cleft → Enhanced dopaminergic signaling via D1 and D2 receptors → ↑ cAMP (D1) or ↓ cAMP (D2) → Downstream effects on motivation, movement, and reward system function
Metabolic Cascade:
- Deprenyl undergoes hepatic N-dealkylation via CYP2B6 and CYP3A4
- Primary metabolites: L-methamphetamine (major) and L-amphetamine (minor)
- L-methamphetamine → Weak CNS stimulation via trace amine-associated receptor 1 (TAAR1) → ↑ norepinephrine release (mild)
- L-amphetamine → β-phenylethylamine formation → Additional dopamine release (presynaptic vesicle mobilization)
Dose-Dependent Selectivity:
- <10 mg/day: 90-95% selective for MAO-B (IC₅₀ ~0.05 μM for MAO-B vs 30 μM for MAO-A)
-
10 mg/day: Begins inhibiting MAO-A → Affects Serotonin, norepinephrine, and tyramine metabolism → Risk of hypertensive crisis (cheese effect)
Neuroprotective Mechanisms (MAO-independent):
- ↑ Expression of neurotrophic factors (BDNF, NGF) via activation of PKC and ERK1-2 pathways
- ↓ Reactive oxygen species (ROS) production by preventing Dopamine auto-oxidation
- ↑ Superoxide dismutase (SOD) and catalase expression via NF-kB modulation
- ↓ Apoptosis via upregulation of Bcl-2 family proteins
graph TD
A[Deprenyl] -->|Irreversible binding| B[MAO-B inhibition]
B --> C["↓ Dopamine degradation"]
C --> D["↑ Synaptic dopamine"]
D --> E[D1 receptor activation]
D --> F[D2 receptor activation]
E --> G["↑ cAMP/PKA"]
F --> H["↓ cAMP"]
G --> I[Enhanced motivation/reward]
H --> J[Motor regulation]
A -->|Hepatic metabolism| K[L-methamphetamine]
A -->|Hepatic metabolism| L[L-amphetamine]
K --> M[TAAR1 activation]
L --> N[Vesicular DA release]
M --> O[Mild NE release]
N --> O
O --> P[Stimulant effects]
B -->|Independent pathway| Q["↑ BDNF/NGF"]
B -->|Independent pathway| R["↓ ROS"]
B -->|Independent pathway| S["↑ SOD/Catalase"]
Q --> T[Neuroprotection]
R --> T
S --> T
Enzyme Regeneration:
- New MAO-B synthesis required to restore enzymatic activity
- Half-life of effect: 40-60 hours (despite 2-hour plasma half-life)
- Full enzymatic recovery: 7-14 days after discontinuation
Deprenyl addresses a critical therapeutic gap in cPNI practice: patients with reward deficiency syndrome who cannot mount adequate dopaminergic responses to lifestyle interventions alone. This is particularly relevant in three clinical scenarios:
1. Structural Dopamine Deficiency States:
- Parkinson's Disease (substantia nigra degeneration)
- Post-stroke corpus callosum function impairment (reduced interhemispheric dopamine coordination)
- Traumatic brain injury sequelae with basal ganglia involvement
- Clinical threshold: Subjective anhedonia score >15/30 on Snaith-Hamilton Pleasure Scale (SHAPS) combined with motor slowing (psychomotor retardation >2 SD below age norms)
2. Metabolic-Immune-Driven Dopamine Dysregulation:
- Depression with high IL-6 (>10 pg/mL) and TNF-α (>8 pg/mL)—cytokines upregulate IDO and reduce tetrahydrobiopterin (BH4), limiting tyrosine hydroxylase activity
- Chronic fatigue syndrome with documented HPA-axis dysfunction (cortisol awakening response <2.5 nmol/L increase)
- Long COVID with persistent anosmia (olfactory dopamine neurons affected)
- Mechanism: Deprenyl bypasses the synthesis bottleneck by extending the half-life of whatever dopamine is produced
3. Evolutionary Mismatch and Motivation Disorders:
- Modern sedentary environments fail to trigger sufficient dopamine release (Hunter-Gatherer Metabolism mismatch)
- ADHD with reward delay intolerance—cannot sustain effort without immediate dopamine feedback
- Addiction recovery—restoring natural reward sensitivity while MAO-B activity remains chronically upregulated from substance use
- Deprenyl recalibrates the reward system to allow incremental lifestyle changes (exercise, cold exposure, social bonding) to register as rewarding
Intervention Protocol (cPNI Context):
- Start 2.5-5 mg/day (morning dosing to avoid insomnia from metabolite stimulation)
- Combine with L-tyrosine (500-1000 mg) and Vitamin B6 (P5P, 25-50 mg) to ensure adequate dopamine precursors
- Monitor for Orthostatic hypotension (MAO-B inhibition can reduce peripheral norepinephrine degradation)
- Avoid tyramine-rich foods only at doses >10 mg/day (cheese, aged meats, fermented foods)
- Therapeutic window: 4-8 weeks for full motivational/cognitive effects; 2-3 days for initial mood lift
Connection to Metamodels:
- Metamodel 0 (Evolutionary mismatch): Addresses reduced dopamine tone from lack of novelty-seeking behavior in modern life
- Metamodel 1 (Chronic stress): Cortisol-induced downregulation of D2 receptors partially compensated by increased dopamine availability
- Metamodel 3 (Gut-brain): Can reduce gut dysbiosis-driven inflammation indirectly by improving vagal tone (dopamine → ↑ Acetylcholine via D2 receptors on vagal motor neurons)
Biomarker Monitoring:
- Homovanillic acid (HVA) in urine: Expected ↓ 20-40% (reduced dopamine metabolism)
- CRP and IL-6: May decrease 15-25% if depression/fatigue was inflammation-driven
- Subjective energy/motivation scales: Expected ↑ within 1 week
- Selectivity window: MAO-B-selective at ≤10 mg/day; MAO-A inhibition begins at >15 mg/day
- Plasma half-life: 2 hours, but pharmacodynamic effect lasts 40-60 hours due to irreversible enzyme binding
- Metabolites: L-methamphetamine (70%), L-amphetamine (30%)—account for 10-15% of clinical stimulant effect
- Neuroprotection: ↑ BDNF by 30-50% in animal models; ↑ SOD activity by 25-35%
- Dopamine increase: 20-40% elevation in striatal dopamine at therapeutic doses (PET imaging studies)
- MAO-B location: Primarily in glia (astrocytes) and serotonergic neurons; MAO-A in dopaminergic neurons—hence deprenyl's glial target specificity
- Enzyme recovery: 10-14 days required for 50% restoration of MAO-B activity after discontinuation
- Clinical onset: Mood/motivation effects within 3-7 days; neuroprotective effects cumulative over 4-12 weeks
- Tyramine interaction: Hypertensive crisis risk minimal at ≤10 mg/day (MAO-A in gut still active to metabolize dietary tyramine)
- CYP interactions: Substrate of CYP2B6, CYP3A4—avoid strong inhibitors (ritonavir, ketoconazole) which ↑ amphetamine metabolite formation
- Dopamine — primary neurotransmitter increased by preventing degradation
- MAO-B — the mitochondrial enzyme selectively and irreversibly inhibited
- Parkinson's Disease — primary clinical indication; slows disease progression in early stages
- reward deficiency — core indication in cPNI for anhedonia and motivational collapse
- anhedonia — direct therapeutic target via enhanced dopaminergic signaling
- motivation — improved through increased D1 receptor activation in ventral striatum
- Corpus Callosum Function — supports interhemispheric dopamine coordination when structurally compromised
- L-tyrosine — synergistic dopamine precursor; combines well to maximize synthesis
- Mucuna pruriens — alternative L-DOPA source; deprenyl extends its half-life
- BDNF — upregulated via MAO-independent neuroprotective pathway
- Depression — effective in treatment-resistant cases with inflammatory biomarkers
- Chronic fatigue syndrome — addresses central dopamine deficiency component
- ADHD — improves reward delay tolerance and sustained attention
- IL-6 — cytokine that impairs dopamine synthesis; deprenyl bypasses this bottleneck
- TNF-α — reduces dopamine neuron firing; deprenyl compensates by prolonging dopamine availability
- Addiction — aids recovery by restoring natural reward sensitivity
- HPA-axis — modulated indirectly via dopamine's influence on CRH neurons in hypothalamus
- Acetylcholine — indirectly enhanced via D2 receptor activation on cholinergic interneurons
- Chronic stress — deprenyl partially reverses cortisol-induced D2 receptor downregulation
- Neuroinflammation — reduced via decreased dopamine auto-oxidation and ROS formation
- CYP450 — metabolized by CYP2B6 and CYP3A4; clinically relevant drug interactions
- Oxidative Stress — reduced by preventing dopamine quinone formation
- Long COVID — emerging indication for persistent fatigue and cognitive dysfunction